Istvan Mucsi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Istvan Mucsi has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
M. Novak
University Health Network, Toronto, Canada
4 shared publicationsMarta Novak
Semmelweis University
4 shared publications- Miklos Zsolt Molnar
Transplant Institute, University of Rochester Medical Center , Rochester, NY
4 shared publications Adam Remport
Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary
2 shared publicationsAgnes Kovacs
Institute of Behavioral Sciences
2 shared publicationsC. Richardson
2 shared publications
Latest Publications
- 1 June 2017
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 97, 165
Psychosocial distress in chronic kidney disease: Benefits of kidney transplantation
- 1 June 2017
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 97, 165
Psychosocial distress in chronic kidney disease: Benefits of kidney transplantation
- 1 June 2017
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 97, 141-142
African Canadian dialysis patients are less likely to have a potential living donor identified compared to Caucasians
- 1 June 2017
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 97, 141-142
African Canadian dialysis patients are less likely to have a potential living donor identified compared to Caucasians
- 1 December 2013
- Published by Elsevier in Sleep Medicine
- Vol. 14, e248
High frequency spectral power of sleep EEG increases with depressive and insomnia symptoms in kidney transplant recipients
- 1 December 2013
- Published by Elsevier in Sleep Medicine
- Vol. 14, e248
High frequency spectral power of sleep EEG increases with depressive and insomnia symptoms in kidney transplant recipients
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
P01-312 - Quality of life and inflammation in patients with kidney transplant
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
P01-312 - Quality of life and inflammation in patients with kidney transplant
- 1 July 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90, 107
CLINICAL AND SOCIO-DEMOGRAPHIC DETERMINANTS OF UTILITY AMONG PATIENTS WITH RENAL TRANSPLANTATION
- 1 July 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90, 107
CLINICAL AND SOCIO-DEMOGRAPHIC DETERMINANTS OF UTILITY AMONG PATIENTS WITH RENAL TRANSPLANTATION
- 17 July 2007
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (4) , 1459
Reply
- 17 July 2007
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (4) , 1459
Reply
- 1 March 2007
- Published by Akademiai Kiado Zrt. in Acta Physiologica Hungarica
- Vol. 94 (1-2) , 117-131
Epithelial-mesenchymal transition in renal tubular cells in the pathogenesis of progressive tubulo-interstitial fibrosis
Epithelial-mesenchymal transition (EMT) plays an important role in embryogenesis and organ formation. Over the last 10–15 years it has been established that EMT is a significant mechanism of tumor progression and metastasis formation and also of progressive tissue fibrosis in the kidney, liver and lung. EMT seen in these diverse physiological and pathophysiological contexts shares a number of stages and modules, but also carries distinct, context specific characteristics. EMT in tissue fibrosis is a form of reverse embryogenesis, when highly specialized epithelial cells in the specific organs will respond to injury with loosing their epithelial characteristics and functions and regaining characteristics of the cells from which they originated. EMT in the context of tissue fibrosis can be induced by different forms of injury or a set of humoral factors. The process is regulated by a complex balance of humoral and microenvironmental stimuli, in which cell-cell contacts and interaction of the transitioning cell with the extracellular matrix components is very important. Intense research in this exciting field yielded good understanding of many of the details of this fascinating process, although numerous questions still await proper answers. There is indication that understanding of the molecular mechanisms underlying “fibrotic” EMT may lead to the design of specific and effective therapeutic measures for progressive tissue fibrosis
- 1 March 2007
- Published by Akademiai Kiado Zrt. in Acta Physiologica Hungarica
- Vol. 94 (1-2) , 117-131
Epithelial-mesenchymal transition in renal tubular cells in the pathogenesis of progressive tubulo-interstitial fibrosis
Epithelial-mesenchymal transition (EMT) plays an important role in embryogenesis and organ formation. Over the last 10–15 years it has been established that EMT is a significant mechanism of tumor progression and metastasis formation and also of progressive tissue fibrosis in the kidney, liver and lung. EMT seen in these diverse physiological and pathophysiological contexts shares a number of stages and modules, but also carries distinct, context specific characteristics. EMT in tissue fibrosis is a form of reverse embryogenesis, when highly specialized epithelial cells in the specific organs will respond to injury with loosing their epithelial characteristics and functions and regaining characteristics of the cells from which they originated. EMT in the context of tissue fibrosis can be induced by different forms of injury or a set of humoral factors. The process is regulated by a complex balance of humoral and microenvironmental stimuli, in which cell-cell contacts and interaction of the transitioning cell with the extracellular matrix components is very important. Intense research in this exciting field yielded good understanding of many of the details of this fascinating process, although numerous questions still await proper answers. There is indication that understanding of the molecular mechanisms underlying “fibrotic” EMT may lead to the design of specific and effective therapeutic measures for progressive tissue fibrosis
- 1 January 2006
- Published by Springer Nature in Drugs
- Vol. 66 (5) , 607-624
Management of Restless Legs Syndrome in Patients on Dialysis
Restless legs syndrome (RLS) is characterised by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on...
- 1 January 2006
- Published by Springer Nature in Drugs
- Vol. 66 (5) , 607-624
Management of Restless Legs Syndrome in Patients on Dialysis
Restless legs syndrome (RLS) is characterised by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on...
- 1 October 2005
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 64 (10) , 288-294
Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis
An increasing amount of evidence suggests that 25-hydroxy vitamin D3 (25(OH)D3) may contribute to the bone health of patients with chronic kidney disease (CKD). The underlying vitamin D status of these patients, however, has often been neglected. In a cross-sectional study we assessed the association between vitamin D status and parathyroid function, bone turnover, bone mass and structure in patients on maintenance hemodialysis. 69 patients on maintenance hemodialysis were assessed by bone densitometry (DEXA) and quantitative bone ultrasound (QUS). Serum 25-hydroxy vitamin D3 levels, serum markers of bone turnover and clinical data were tabulated. A high prevalence of potentially significant vitamin D3 deficiency was found in this patient group: 59% of the patients had a 25(OH)D3 level below 20 nmol/l. There was a significant negative correlation between serum 25(OH)D3 levels and serum intact parathyroid hormone (iPTH) (r = -0.231, p < 0.05), and this association remained significant after controlling for potential covariables. Furthermore, we show here that serum 25(OH)D3 concentration is positively correlated with bone mineral density (BMD) measured at the radius (r = 0.424, p < 0.01). Finally, we show for the first time that 25(OH)D3 levels are significantly and independently correlated with broadband ultrasound attenuation (beta = 0.262, p < 0.05) measured with calcaneal quantitative bone ultrasound (QUS) in patients with chronic renal failure. Vitamin D3 deficiency may contribute to the impaired bone health of patients on maintenance dialysis.
- 1 October 2005
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 64 (10) , 288-294
Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis
An increasing amount of evidence suggests that 25-hydroxy vitamin D3 (25(OH)D3) may contribute to the bone health of patients with chronic kidney disease (CKD). The underlying vitamin D status of these patients, however, has often been neglected. In a cross-sectional study we assessed the association between vitamin D status and parathyroid function, bone turnover, bone mass and structure in patients on maintenance hemodialysis. 69 patients on maintenance hemodialysis were assessed by bone densitometry (DEXA) and quantitative bone ultrasound (QUS). Serum 25-hydroxy vitamin D3 levels, serum markers of bone turnover and clinical data were tabulated. A high prevalence of potentially significant vitamin D3 deficiency was found in this patient group: 59% of the patients had a 25(OH)D3 level below 20 nmol/l. There was a significant negative correlation between serum 25(OH)D3 levels and serum intact parathyroid hormone (iPTH) (r = -0.231, p < 0.05), and this association remained significant after controlling for potential covariables. Furthermore, we show here that serum 25(OH)D3 concentration is positively correlated with bone mineral density (BMD) measured at the radius (r = 0.424, p < 0.01). Finally, we show for the first time that 25(OH)D3 levels are significantly and independently correlated with broadband ultrasound attenuation (beta = 0.262, p < 0.05) measured with calcaneal quantitative bone ultrasound (QUS) in patients with chronic renal failure. Vitamin D3 deficiency may contribute to the impaired bone health of patients on maintenance dialysis.
- 24 August 2005
- Published by Wiley in Clinical Transplantation
- Vol. 19 (6) , 825-833
Anemia in kidney transplanted patients
Abstract: Background: Although a known cardiovascular risk factor, anemia in the renal transplant recipients has only recently been receiving an increasing attention.Methods: In a cross‐sectional study, data was obtained from 959 patients followed at a single outpatient transplant clinic. Based on the guideline of the American Society of Transplantation, anemia was defined as hemoglobin (Hb) 130 g/L in males and 120 g/L in females.Results: About one‐third (34%) of the patients were anemic. The prevalence of anemia was comparable in males and females. Serum Hb concentration was significantly correlated with the estimated glomerular filtration rate (eGFR) (abbreviated modification of diet in renal disease formula) (r = 0.266, p < 0.001), serum transferrin (r = 0.268, p < 0.001) and serum albumin (r = 0.196, p < 0.001). None of the immunosuppressive medications or the use of angiotensin converting enzyme inhibitors was associated with a higher likelihood of anemia. In multivariate analysis the eGFR, serum albumin and serum transferrin, potential markers of nutritional status and/or chronic inflammation, and also iron deficiency were independently and significantly associated with anemia. Erythropoietin was administered only to 63 (19%) anemic patients.Conclusions: Post‐transplant anemia is a prevalent and under‐treated condition. Based on our results we suggest that, besides other factors, protein/energy malnutrition and/or chronic inflammation may be independently associated with anemia. Further studies are needed to determine whether the presence of anemia and its treatment will have an impact on long‐term outcomes of this population.
- 24 August 2005
- Published by Wiley in Clinical Transplantation
- Vol. 19 (6) , 825-833
Anemia in kidney transplanted patients
Abstract: Background: Although a known cardiovascular risk factor, anemia in the renal transplant recipients has only recently been receiving an increasing attention.Methods: In a cross‐sectional study, data was obtained from 959 patients followed at a single outpatient transplant clinic. Based on the guideline of the American Society of Transplantation, anemia was defined as hemoglobin (Hb) 130 g/L in males and 120 g/L in females.Results: About one‐third (34%) of the patients were anemic. The prevalence of anemia was comparable in males and females. Serum Hb concentration was significantly correlated with the estimated glomerular filtration rate (eGFR) (abbreviated modification of diet in renal disease formula) (r = 0.266, p < 0.001), serum transferrin (r = 0.268, p < 0.001) and serum albumin (r = 0.196, p < 0.001). None of the immunosuppressive medications or the use of angiotensin converting enzyme inhibitors was associated with a higher likelihood of anemia. In multivariate analysis the eGFR, serum albumin and serum transferrin, potential markers of nutritional status and/or chronic inflammation, and also iron deficiency were independently and significantly associated with anemia. Erythropoietin was administered only to 63 (19%) anemic patients.Conclusions: Post‐transplant anemia is a prevalent and under‐treated condition. Based on our results we suggest that, besides other factors, protein/energy malnutrition and/or chronic inflammation may be independently associated with anemia. Further studies are needed to determine whether the presence of anemia and its treatment will have an impact on long‐term outcomes of this population.